Table 2. Plasma syndecan-1, heparan sulfate and chondroitin sulfate concentrations during graft reperfusion.
| Syndecan-1 (ng/ml) | Heparan sulfate (ng/ml) | Chondroitin sulfate ng/ml) | ||
|---|---|---|---|---|
| Reperfusion | ||||
| Portal vein | 101 (75–121) | 112 (98–128) | 12.7 (0.95–76.1) | |
| Caval effluent | 3118 (934–6141) | 96 (32–129) | 10.4 (0.5–73.1) | |
| Transhepatic gradient1 | 3013 (814–6036)** | -15 (-81–8)* | 0.5 (-11.0–3.3) | |
| 5 min after portal vein declamping | ||||
| Portal vein | 379 (202–830) | 102 (73–126) | 6.9 (0.5–40.6) | |
| Hepatic vein | 1038 (202–2207) | 102 (74–128) | 7.7 (0.6–44.0) | |
| Transhepatic gradient | 514 (220–1528)** | 2 (-37–26) | 0.1 (-1.4–3.4) | |
| 5 min after hepatic artery declamping | ||||
| Portal vein | 1565 (515–3590) | 36 (31–55) | 8.3 (0.25–37.7) | |
| Hepatic vein | 1294 (583–3590) | 30 (21–56) | 7.6 (0.3–39.6) | |
| Transhepatic gradient | -165 (-2236–468) | -4 (-31–23) | 0.1 (-2.0–1.9) | |
Data are expressed as median (range).
1 [(caval effluent or hepatic vein)–(portal vein)].
* P <0.05
** P < 0.01 (hepatic vs portal vein, Wilcoxon Signed Rank test).